

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Luzhu Biotechnology Co., Ltd.
北京綠竹生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2480)

INSIDE INFORMATION
ISSUANCE OF FILING NOTICE BY THE CSRC
FOR THE H SHARE FULL CIRCULATION PROGRAMME
OF THE COMPANY

This announcement is made by Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated December 28, 2023 in relation to the proposed participation in the H share full circulation programme by the Company (the “**Announcement on Participation**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement on Participation.

The Company is pleased to announce that the Company has received a filing notice dated January 17, 2024 (the “**Filing Notice**”) issued by the CSRC in respect of the implementation of the H Shares full circulation programme of the Company. According to the Filing Notice, the Company has completed the filing with the CSRC in respect of the implementation of conversion up to an aggregate of 59,729,296 Unlisted Shares, comprising 58,294,513 Unlisted Shares owned by Mr. KONG Jian (孔健) and 1,434,783 Unlisted Shares owned by Beijing Xinyin Xinghong Equity Investment Partnership (Limited Partnership) (北京信銀興弘股權投資合夥企業(有限合夥)), into H Shares. The Company will apply to the Stock Exchange for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange (the “**Conversion and Listing**”).

Further, Mr. KONG Jian (孔健), one of the controlling shareholders of the Company, has voluntarily undertaken not to dispose of any shares of the Company owned by him for a period of two years commencing from the date of completion of the Conversion and Listing, to demonstrate his confidence in the long-term prospect of the Group.

As at the date of this announcement, the details of implementation plan of the Conversion and Listing have not been finalized. The Company will make further announcements on the progress of the Conversion and Listing in compliance with the requirements under Listing Rules and the applicable laws, as and when appropriate.

The Conversion and Listing are subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, January 17, 2024

As at the date of this announcement, the Board comprises Mr. KONG Jian, Ms. JIANG Xianmin and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Mr. LEUNG Wai Yip, Mr. LIANG Yeshe and Ms. HOU Aijun as independent non-executive Directors.